Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic Nasopharyngeal Carcinoma After First-line Treatment Failure
NCT07101744Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Oct 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07101744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101744.